JP2022501402A - Cd8イメージングコンストラクト及びその使用方法 - Google Patents
Cd8イメージングコンストラクト及びその使用方法 Download PDFInfo
- Publication number
- JP2022501402A JP2022501402A JP2021517437A JP2021517437A JP2022501402A JP 2022501402 A JP2022501402 A JP 2022501402A JP 2021517437 A JP2021517437 A JP 2021517437A JP 2021517437 A JP2021517437 A JP 2021517437A JP 2022501402 A JP2022501402 A JP 2022501402A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- tumor
- binding construct
- human
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C)NC(Nc1ccc(C)cc1)=S Chemical compound C*(C)NC(Nc1ccc(C)cc1)=S 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218898A JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Cd8イメージングコンストラクト及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738938P | 2018-09-28 | 2018-09-28 | |
| US62/738,938 | 2018-09-28 | ||
| US201962826606P | 2019-03-29 | 2019-03-29 | |
| US62/826,606 | 2019-03-29 | ||
| PCT/US2019/053642 WO2020069433A1 (en) | 2018-09-28 | 2019-09-27 | Cd8 imaging constructs and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218898A Division JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Cd8イメージングコンストラクト及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022501402A true JP2022501402A (ja) | 2022-01-06 |
| JP2022501402A5 JP2022501402A5 (cg-RX-API-DMAC7.html) | 2022-10-05 |
Family
ID=69949940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517437A Pending JP2022501402A (ja) | 2018-09-28 | 2019-09-27 | Cd8イメージングコンストラクト及びその使用方法 |
| JP2024218898A Pending JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Cd8イメージングコンストラクト及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218898A Pending JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Cd8イメージングコンストラクト及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220001043A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4205769A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022501402A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210087938A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116271117A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019351264B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3113080A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020069433A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024143263A1 (ja) | 2022-12-26 | 2024-07-04 | 富士フイルム株式会社 | 蛍光強度増強剤、蛍光標識された標的生体物質の蛍光強度増強方法、及び、蛍光検出用キット |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd8에의 항원 결합 구조체들 |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| AU2019282248A1 (en) | 2018-06-08 | 2021-01-07 | Imaginab, Inc. | Antigen binding constructs to CD4 |
| GB2584086A (en) * | 2019-05-17 | 2020-11-25 | Univ Oxford Innovation Ltd | A method for identity validation and quality assurance of quantitative magnetic resonance imaging protocols |
| JP7810446B2 (ja) * | 2020-09-17 | 2026-02-03 | サニーベイ・バイオテック・インコーポレイテッド | Herv-k抗体治療薬 |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN115927342B (zh) * | 2022-07-08 | 2025-09-23 | 新疆医科大学 | 特异识别CD8α分子的高亲和力核酸适配体 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4590688A1 (en) | 2022-09-21 | 2025-07-30 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| CN116130131B (zh) * | 2022-12-30 | 2026-02-06 | 中国核动力研究设计院 | 一种一回路压力边界泄漏辐射监测装置及其监测方法 |
| JP2026502532A (ja) * | 2023-01-12 | 2026-01-23 | ナショナル ユニバーシティ オブ シンガポール | T細胞及びnk細胞悪性腫瘍の免疫療法のためのcd8発現及びキメラ抗原受容体の遮断 |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025064435A1 (en) | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| US12086990B1 (en) * | 2024-04-23 | 2024-09-10 | MultiFunctional Imaging LLC | Systems and methods for simultaneous imaging of multiple positron emission tomography (PET) tracers |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
| US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
| US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| JP2008539220A (ja) * | 2005-04-26 | 2008-11-13 | ファイザー・リミテッド | バソプレシンアンタゴニストとしてのトリアゾール誘導体 |
| US8557257B2 (en) * | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP4877766B2 (ja) | 2006-08-25 | 2012-02-15 | 独立行政法人放射線医学総合研究所 | 陽電子放射断層撮像装置及び放射線検出器 |
| US20130137975A1 (en) * | 2010-02-09 | 2013-05-30 | OSI Pharmaceuticals, LLC | Pet imaging |
| AU2012212006A1 (en) | 2011-02-03 | 2013-08-15 | California Institute Of Technology | PSA capture agents, compositions, methods and preparation thereof |
| US8993971B2 (en) | 2011-06-15 | 2015-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | High resolution positron emission tomography |
| US9239332B2 (en) | 2011-07-11 | 2016-01-19 | Indi Molecular, Inc. | Akt-specific capture agents, compositions, and methods of using and making |
| US8710180B2 (en) | 2011-08-31 | 2014-04-29 | Indi Molecular, Inc. | VEGF-specific capture agents, compositions, and methods of using and making |
| CA2865774A1 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Psma as a biomarker for androgen activity in prostate cancer |
| US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014074907A1 (en) | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| KR20150131208A (ko) * | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd8에의 항원 결합 구조체들 |
| CN105979872A (zh) | 2013-09-25 | 2016-09-28 | 理查德·R·布莱克 | 正电子发射断层摄影数据的病人特异性分析 |
| DE102014200303B4 (de) | 2014-01-10 | 2015-10-29 | Siemens Aktiengesellschaft | Verfahren zur Durchführung einer Positronenemissionstomographie in einer Hybridanlage und entsprechende Hybridanlage |
| EA201792442A1 (ru) * | 2015-05-06 | 2018-06-29 | Янссен Байотек, Инк. | Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN105395209B (zh) | 2015-12-01 | 2018-10-02 | 沈阳东软医疗系统有限公司 | 一种正电子发射断层扫描成像系统及方法 |
| WO2017176769A1 (en) | 2016-04-04 | 2017-10-12 | Indi Molecular, Inc. | Cd8-specific capture agents, compositions, and methods of using and making |
| CN109414238B (zh) | 2016-06-12 | 2023-01-03 | 上海联影医疗科技股份有限公司 | 正电子发射断层成像系统及其图像重建方法 |
| WO2019033043A2 (en) * | 2017-08-11 | 2019-02-14 | Genentech, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
-
2019
- 2019-09-27 WO PCT/US2019/053642 patent/WO2020069433A1/en not_active Ceased
- 2019-09-27 CA CA3113080A patent/CA3113080A1/en active Pending
- 2019-09-27 CN CN202211648348.2A patent/CN116271117A/zh active Pending
- 2019-09-27 EP EP22182384.2A patent/EP4205769A1/en active Pending
- 2019-09-27 US US17/280,137 patent/US20220001043A1/en active Pending
- 2019-09-27 EP EP19866804.8A patent/EP3856786A4/en active Pending
- 2019-09-27 KR KR1020217012365A patent/KR20210087938A/ko active Pending
- 2019-09-27 CN CN201980079379.0A patent/CN113166255A/zh active Pending
- 2019-09-27 JP JP2021517437A patent/JP2022501402A/ja active Pending
- 2019-09-27 AU AU2019351264A patent/AU2019351264B2/en active Active
-
2024
- 2024-12-13 JP JP2024218898A patent/JP2025060696A/ja active Pending
Non-Patent Citations (3)
| Title |
|---|
| FRONT. PHARMACOL., vol. 7, JPN6024004885, 2016, pages 131, ISSN: 0005560976 * |
| J. NUCL. MED., vol. 59, [Suppl.1], JPN6023032908, May 2018 (2018-05-01), pages 596, ISSN: 0005560975 * |
| 科学研究費助成事業 (学術研究助成基金助成金) 研究成果報告書, 小型サイクロトロンを用いた生体高分子プロ, JPN6024004886, ISSN: 0005390705 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024143263A1 (ja) | 2022-12-26 | 2024-07-04 | 富士フイルム株式会社 | 蛍光強度増強剤、蛍光標識された標的生体物質の蛍光強度増強方法、及び、蛍光検出用キット |
| EP4644874A1 (en) | 2022-12-26 | 2025-11-05 | FUJIFILM Corporation | Fluorescence intensity enhancing agent, method for enhancing fluorescence intensity of fluorescently labeled target biological material, and fluorescence detection kit |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220001043A1 (en) | 2022-01-06 |
| WO2020069433A1 (en) | 2020-04-02 |
| CA3113080A1 (en) | 2020-04-02 |
| EP3856786A1 (en) | 2021-08-04 |
| EP4205769A9 (en) | 2023-08-23 |
| AU2019351264A1 (en) | 2021-04-29 |
| CN116271117A (zh) | 2023-06-23 |
| KR20210087938A (ko) | 2021-07-13 |
| JP2025060696A (ja) | 2025-04-10 |
| EP4205769A1 (en) | 2023-07-05 |
| EP3856786A4 (en) | 2022-07-20 |
| AU2019351264B2 (en) | 2026-07-02 |
| CN113166255A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025060696A (ja) | Cd8イメージングコンストラクト及びその使用方法 | |
| JP6050466B2 (ja) | 腫瘍特異的抗体及びその使用法 | |
| US11427648B2 (en) | Anti-CD146 antibodies and uses thereof | |
| JP5906090B2 (ja) | 癌の診断のための方法およびキットならびに治療価の推定 | |
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| Hall et al. | Imaging prostate cancer lymph node metastases with a multimodality contrast agent | |
| Achmad et al. | Predicting cetuximab accumulation in KRAS wild‐type and KRAS mutant colorectal cancer using 64Cu‐labeled cetuximab positron emission tomography | |
| Tolmachev et al. | Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels | |
| Shooli et al. | Theranostics in brain tumors | |
| Wei et al. | Development and characterization of CD54-targeted immunoPET imaging in solid tumors | |
| Ku et al. | MicroSPECT/CT imaging of cell-line and patient-derived EGFR-positive tumor xenografts in mice with panitumumab fab modified with hexahistidine peptides to enable labeling with 99mTc (I) tricarbonyl complex | |
| WO2024041574A1 (en) | Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates | |
| Storey et al. | Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance | |
| Ghosh et al. | Clinical development of an anti-GPC-1 antibody for the treatment of cancer | |
| JP2017214308A (ja) | 放射性医薬組成物、及び、放射能標識抗体のスクリーニング方法 | |
| Kraeber‐Bodéré et al. | Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer | |
| CA2771316C (en) | Selective detection of bone metastases in renal clear cell carcinoma | |
| Filippi et al. | ImmunoPET for prostate cancer in the PSMA era: do we need other targets? | |
| Movahed et al. | Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective | |
| HK40059336A (en) | Cd8 imaging constructs and methods of use thereof | |
| Kwon | Positron Emission Tomography (PET) of Breast cancer heterogeneous for HER2 and EGFR using bispecific radioimmunoconjugates | |
| Sharma et al. | A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET | |
| Growth | Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast | |
| Bensch | Molecular imaging on the move | |
| McLarty | Molecular Imaging as a Tool for Predicting and Monitoring Response of Breast Cancer to Trastuzumab (Herceptin (R)) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220926 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230814 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240513 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241213 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241220 |